Key result
Baroreflex activation therapy linked to improved quality of life, HRV, and inflammatory biomarkers in HFrEF.
Why the study?
Does baroreflex activation therapy improve autonomic balance and systemic inflammation in patients with advanced HFrEF?
Case Report (n=7)
Does baroreflex activation therapy improve autonomic balance and systemic inflammation in patients with advanced HFrEF?
Baroreflex activation therapy may provide therapeutic benefits in advanced HFrEF through autonomic restoration and anti-inflammatory modulation.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; leaves open BAT's potential via autonomic restoration and anti-inflammatory effects pending randomized trials.
BACKGROUND: Baroreflex activation therapy (BAT) may ameliorate autonomic imbalance in patients after heart failure with reduced ejection fraction (HFrEF); however, its effects on systemic inflammation and autonomic indices remain unknown. CASE SUMMARY: Seven patients with advanced HFrEF underwent BAT implantation. Three cases are presented in detail, illustrating distinct response patterns: clinical improvement, robust parasympathetic restoration, and anti-inflammatory response. DISCUSSION: After BAT, patients demonstrated improvements in quality of life, heart rate variability (HRV), and inflammatory biomarkers (tumor necrosis factor-α, interferon-γ). These preliminary findings suggest that BAT may exert therapeutic benefits through both autonomic restoration and anti-inflammatory modulation. TAKE-HOME MESSAGES: An aggregate analysis of 7 patients with HFrEF who received BAT demonstrated favorable responses in inflammatory biomarkers, HRV, and clinical outcomes. BAT led to decrease in tumor necrosis factor-α and interferon-γ and autonomic balance restoration as measured by HRV. These findings support further investigation into the mechanisms of action of BAT.
No takes yet. Share an insight, caveat, or question.
Bekiaridou et al. (2026) conducted a case report in Heart failure with reduced ejection fraction (HFrEF) (n=7). Baroreflex activation therapy was evaluated on Inflammatory biomarkers, heart rate variability, and clinical outcomes. Baroreflex activation therapy in 7 patients with advanced HFrEF led to decreases in tumor necrosis factor-α and interferon-γ and restored autonomic balance as measured by heart rate variability.
Synapse has enriched 10 related papers. Consider them for comparative context: